Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Kruithof

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Seminars in Thrombosis and Hemostasis|January 1, 1984
Tissue plasminogen activator: chemical and physiological aspectsF Bachmann, I E Kruithof
Annals of the Rheumatic Diseases|August 15, 2002
Tenosynovitis with acute onset: unexpected giant cell tumour of the tendon sheathE Kruithof, D Baeten, P Dierckxsens, et al.
Computers in Biology and Medicine|August 31, 2021
Influence of image artifacts on image-based computer simulations of the cardiac electrophysiologyE Kruithof, S Amirrajab, M J M Cluitmans, et al.
British Journal of Cancer|September 1, 1996
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cellsC Trân-Thang, E Kruithof, H Lahm, et al.
The Journal of Rheumatology|March 15, 2001
Characteristic marco- and microscopic aspect of the synovial membrane in crystal induced arthritisF van den Bosch, D Baeten, E Kruithof, et al.
Lancet (London, England)|December 16, 2000
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptomsF Van den Bosch, E Kruithof, M De Vos, et al.
Cancer Gene Therapy|June 7, 2008
Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma modelF Solly, R Fish, B Simard, et al.
Annals of the Rheumatic Diseases|December 21, 2006
Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placeboB Vander Cruyssen, F De Keyser, E Kruithof, et al.
Annals of the Rheumatic Diseases|June 2, 2000
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot studyF Van den Bosch, E Kruithof, D Baeten, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alphaF Van den Bosch, D Baeten, E Kruithof, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Seminars in Thrombosis and Hemostasis|January 1, 1984
Tissue plasminogen activator: chemical and physiological aspectsF Bachmann, I E Kruithof
Annals of the Rheumatic Diseases|August 15, 2002
Tenosynovitis with acute onset: unexpected giant cell tumour of the tendon sheathE Kruithof, D Baeten, P Dierckxsens, et al.
Computers in Biology and Medicine|August 31, 2021
Influence of image artifacts on image-based computer simulations of the cardiac electrophysiologyE Kruithof, S Amirrajab, M J M Cluitmans, et al.
British Journal of Cancer|September 1, 1996
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cellsC Trân-Thang, E Kruithof, H Lahm, et al.
The Journal of Rheumatology|March 15, 2001
Characteristic marco- and microscopic aspect of the synovial membrane in crystal induced arthritisF van den Bosch, D Baeten, E Kruithof, et al.
Lancet (London, England)|December 16, 2000
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptomsF Van den Bosch, E Kruithof, M De Vos, et al.
Cancer Gene Therapy|June 7, 2008
Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma modelF Solly, R Fish, B Simard, et al.
Annals of the Rheumatic Diseases|December 21, 2006
Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placeboB Vander Cruyssen, F De Keyser, E Kruithof, et al.
Annals of the Rheumatic Diseases|June 2, 2000
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot studyF Van den Bosch, E Kruithof, D Baeten, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alphaF Van den Bosch, D Baeten, E Kruithof, et al.
Pageof 3